BNC-210
BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials. It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
BNC-210
BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials. It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.
has abstract
BNC210 (also known as IW-2143 ...... urrent generation anxiolytics.
@en
CAS number
13589-06-5
PubChem
Wikipage page ID
28,376,300
page length (characters) of wiki page
Wikipage revision ID
1,009,733,485
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
IUPAC name
(L)-Isoleucyl-(L)-tryptophan
@en
legal status
Investigational
@en
PubChem
SMILES
CC[C@H][C@@H]N
@en
StdInChIKey
BVRPESWOSNFUCJ-LKTVYLICSA-N
@en
wikiPageUsesTemplate
comment
BNC210 (also known as IW-2143 ...... in rat discriminatory models.
@en
label
BNC-210
@en